Calithera Biosciences, Inc.
CALADelisted Mar 3, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001496671
Calithera Biosciences, Inc. was delisted on Mar 3, 2023; its insiders filed their last Form 4 on May 26, 2023; 29 institutions reported holding it in 13F filings for Q2 2022, worth $4.44M in total; no superinvestor held it.
Holders of 5% or more of CALA
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Calithera Biosciences, Inc., largest stake first. The change is against the holder's previous filing.
No holder currently reports owning 5% or more of Calithera Biosciences, Inc. on Schedule 13D or 13G.
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
25 Schedule 13D and 13G filings on Calithera Biosciences, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| May 26, 20237:08 AM ET | Takeda Pharmaceutical Co Ltd | 13D/AOld format | – | – | – | SEC |
| Feb 14, 2023 | Citadel Advisors LLC | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2023 | Biotechnology Value Fund L P | 13G/AOld format | – | – | – | SEC |
| Feb 9, 2023 | Primecap Management Co | 13G/AOld format | – | – | – | SEC |
| Feb 9, 2023 | Primecap Management Co | 13G/AOld format | – | – | – | SEC |
| Feb 8, 20234:05 PM ET | Incyte Corp | 13G/AOld format | – | – | – | SEC |
| Dec 8, 2022 | Primecap Management Co | 13G/AOld format | – | – | – | SEC |
| Jul 6, 2022 | Takeda Pharmaceutical Co Ltd | 13D/AOld format | – | – | – | SEC |
| Apr 21, 2022 | Takeda Pharmaceutical Co Ltd | 13DOld format | – | New | – | SEC |
| Apr 11, 2022 | Citadel Advisors LLC | 13GOld format | – | – | – | SEC |
| Feb 14, 2022 | Citadel Advisors LLC | 13G/AOld format | – | – | – | SEC |
| Feb 10, 2022 | Primecap Management Co | 13G/AOld format | – | – | – | SEC |
| Feb 10, 2022 | Adage Capital Partners GP, L.L.C. | 13G/AOld format | – | – | – | SEC |
| Feb 9, 2022 | Vanguard Group Inc | 13G/AOld format | – | – | – | SEC |
| Dec 10, 20211:13 PM ET | Federated Hermes, Inc. | 13G/AOld format | – | – | – | SEC |
| Nov 22, 2021 | Citadel Advisors LLC | 13GOld format | – | New | – | SEC |
| Jul 12, 20218:29 AM ET | BlackRock Inc. | 13G/AOld format | – | – | – | SEC |
| Jul 8, 2021 | Biotechnology Value Fund L P | 13G/AOld format | – | – | – | SEC |
| Feb 16, 2021 | Point72 Asset Management, L.P. | 13G/AOld format | – | – | – | SEC |
| Feb 12, 20211:18 PM ET | Federated Hermes, Inc. | 13G/AOld format | – | – | – | SEC |
| Feb 12, 2021 | Primecap Management Co | 13G/AOld format | – | – | – | SEC |
| Feb 11, 2021 | Biotechnology Value Fund L P | 13G/AOld format | – | – | – | SEC |
| Feb 10, 2021 | Vanguard Group Inc | 13GOld format | – | New | – | SEC |
| Jan 28, 20215:55 PM ET | BlackRock Inc. | 13G/AOld format | – | – | – | SEC |
| Jan 25, 2021 | Adage Capital Partners GP, L.L.C. | 13GOld format | – | New | – | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Calithera Biosciences, Inc. shares.
No Form 144 notices for Calithera Biosciences, Inc. are on file.